Mporium Share Discussion Threads

[philjeans] 06/7/2009 07:54

A small step but it could be highly significant.

Await further developments.

[jimmyloser] 06/7/2009 07:28

Encouraging news - still waitng for mpm to play its cards.

[fruitloops101] 06/7/2009 07:23

For anyone wanting to read the article in the Lancet referred to in today's RNS:

[philjeans] 30/6/2009 15:39

So; two new directors, both ex- GSK, both highly skilled in this business with prior knowledge of the products/patents and with massive kudos and a wealth of contacts.

Enough cash for two years and a strong drive to commercialisation.

Time to buy methinks - topped up today.

[dryboy2] 30/6/2009 15:38

Balcony any info as to why you think this could rise

[simonparker5] 30/6/2009 08:42

balcony - agreed.

[balcony] 30/6/2009 08:13

I am surprized no one as picked up on these yet,I think we might have a multi-bagger in the making

[spitfire3] 11/6/2009 11:03

he is probably using another name again

[gartshore] 06/6/2009 19:53

whatever nappened to harrypunter

[dryboy2] 28/5/2009 14:56

sling your hook busthief you pranock

[monkey puzzle] 28/5/2009 09:39

Still burning through the cash though......

[balcony] 28/5/2009 07:47

Jimmy-Yes so much that you may have to change your name.

[jimmyloser] 28/5/2009 07:31

This says it all for me.....hold on tight. imo


The Board intends to evaluate..... 'all opportunities'..... to build shareholder value through our existing pipeline assets, our revitalised management team and our willingness to consider all options to deliver our ultimate goal of building a profitable business.

[busthief2] 22/5/2009 16:30

Hello Dryboy, hav,nt heard from you since you lost ur shirt on bioglan!!

[hugepants] 19/5/2009 19:07

Neuropharm(NPH) is similar. It had 30p net cash at end of 2008. Current price 13.5p. News due soon on future strategy.

[philjeans] 19/5/2009 18:57

Regulatory News Service from the London Stock Exchange.

[dryboy2] 19/5/2009 17:15

excuse me for being thick,whats an RNS ?

[philjeans] 19/5/2009 14:35

More interest again today and price continues to edge up.

A significant RNS will send it into orbit.

[philjeans] 18/5/2009 13:49

A little more background on the " new boy";

Karl Keegan

Managing Director (Life Sciences), Canaccord Capital

Karl Keegan joined Canaccord Capital in July 2003, from Banc of America Securities where he developed a European Life Sciences franchise. He has also served as an analyst with UBS Warburg and Dresdner Kleinwort Benson. Prior, Karl gained practical industry experience in both research and strategic product development at SmithKline Beecham Pharmaceuticals. He earned a degree in Pharmacology from University College, Dublin, followed by a MPhil and PhD in Biophysics from Cambridge University. Karl completed his postdoctoral training at Baylor College of Medicine, Texas.


Can you imagine anyone with better qualifications; contacts, knowledge, city nous; awareness of which growth businesses are looking for a float/cash shell; experience of driving on a tiny pharma?

I can't; bought some more.

[jimmyloser] 18/5/2009 11:39

Agree with philjeans - if you are a speculator, the odds are that most of you will be disappointed.

ltb. methinks


imo.

[mikey34] 18/5/2009 11:21

Tend to agree Lyntwyn.The only difference from Friday is the article about speculative possibilities.

[lyntwyn] 18/5/2009 10:36

buy tomorrow- will be back circa 5p. this isn't up today an new news, just media hype.

[philjeans] 18/5/2009 10:08

The new appointment is company transforming - no way he would jump ship from such a prestigious and well paid position to this micro without good cause.

Cash in the bank; tax losses galore; quote already - ready made shell.

Multi bagger from here. Forget about the rise so far - many more like this to come.

RNS in due course.

[monkey puzzle] 18/5/2009 09:50

Good call Jimmy.......are going for ltb&h or quick buck?